Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 516-526

  Kiyota, Miki ^a   Kobayashi, Tsutomu ^a   Fuchida, Shinichi ^b   Yamamoto Sugitani, Mio ^a   Ohshiro, Muneo ^a   Shimura, Yuji ^a   Mizutani, Shinsuke ^a   Nagoshi, Hisao ^a   Sasaki, Nana ^a   Nakayama, Ryuko ^a   Yoshiaki, Chinen ^a   Sakamoto, Natsumi ^a   Uchiyama, Hitoji ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Shimazaki, Chihiro ^b   Kuroda, Junya ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kyoto Social Insurance Hospital   (Japan)

Author keywords

Bortezomib; Chromosome 13 abnormalities; Metaphase spreads; Multiple myeloma; Prognosis

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME DELETION 13; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 4; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LONG TERM CARE; MALE; METAPHASE; MONOSOMY; MONOSOMY 13; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DEXAMETHASONE; FEMALE; HUMANS; MALE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862905349     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1035-8     Document Type: Article

References (62)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
2. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, riskstratification, and management. Am J Hematol. 2011;86:57-65.
3. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116: 2543-53.
4. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. Molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-21.
5. Smadja NV, Bastard C, Brigaudeau C, Leroux D. Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-38.
6. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-75. (Pubitemid 36857829)
7. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-95. (Pubitemid 46572539)
8. Fonseca R, Bariogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-58. (Pubitemid 38235629)
9. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-8. (Pubitemid 44395016)
10. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90: 526-34. (Pubitemid 27299091)
11. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-41. (Pubitemid 46348934)
12. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117(18): 4696-700.
13. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94:310-20.
14. Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-12. (Pubitemid 30106611)
15. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250-6.
16. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-71. (Pubitemid 32217218)
17. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041-7. (Pubitemid 35025967)
18. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610-7. (Pubitemid 44264105)
19. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034-40. (Pubitemid 44614894)
20. Kobayashi T, Kuroda J, Kiyota M, Nakayama R, Taniwaki M. Clinical studies of molecular targeted therapy for multiple myeloma. Transl Medic (in press).
21. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-17. (Pubitemid 36741588)
22. Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143:46-53.
23. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429-35. (Pubitemid 46698286)
24. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537-40.
25. Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol. 2010;92:579-86.
26. Igarashi N, Chou T, Hirose T, Imai Y, Ishiguro T. Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. Int J Hematol. 2010;92:518-23.
27. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. SUMMIT/CREST Investigators. Cancer. 2005;103:1195-200.
28. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842-9. (Pubitemid 351552634)
29. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma. 2008;8:352-5.
30. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian myeloma network GIMEMA. Eur J Haematol. 2010;84:223-8.
31. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27:6086-93.
32. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151-7. (Pubitemid 44921846)
33. Chang H, Trieu Y, Qi XY, Xu W, Stewart K. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/ refractory multiple myeloma. Leuk Res. 2007;33:779-82. (Pubitemid 46855891)
34. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007;21:164-8. (Pubitemid 44921848)
35. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28: 4630-4.
36. Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21:143-50. (Pubitemid 44921845)
37. San-Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-17.
38. Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol. 2009;147:347-51.
39. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60.
40. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593-9.
41. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of dose-modification guideline. Br J Haematol. 2009;144:895-903.
42. Nakazawa N, Nishida K, Tamura A, Kobayashi M, Iwai T, Horiike S, et al. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. Cancer Genet Cytogenet. 2000;117:89-96. (Pubitemid 30125805)
43. Taniwaki M, Matsuda F, Jauch A, Nishida K, Takashima T, Tagawa S, et al. Detection of 14q32 translocations in B-cell malignancies by in situ hybridization with yeast artificial chromosome clones containing the human IgH gene locus. Blood. 1994;83:2962-9. (Pubitemid 24142730)
44. Chinen Y, Taki T, Nishida K, Shimizu D, Okuda T, Yoshida N, et al. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene. 2008;27:2249-56. (Pubitemid 351483379)
45. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73. (Pubitemid 44264086)
46. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10:117-26. (Pubitemid 41829514)
47. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724-32. (Pubitemid 44316143)
48. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562-7. (Pubitemid 37193596)
49. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-30. (Pubitemid 30151627)
50. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;99:1566-71. (Pubitemid 32217218)
51. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, et al. Prognostic factors for hyperdiploidmyeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807-13.
52. Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003;120:44-52. (Pubitemid 36056907)
53. Fuhler GM, Diks SH, Peppelenbosch MP, Kerr WG. Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention. Mol Med. 2011;17(7-8):790-8.
54. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106-13. (Pubitemid 37021949)
55. López-Corral L, Gutiérrez NC, Vidriales MB, Mateos MV, Rasillo A, García-Sanz R, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17:1692-700.
56. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-22.
57. Avet-Loiseau H. Ultra high-risk myeloma. Hematol Am Soc Hematol Educ Program. 2010;2010:489-93.
58. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
59. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111: 2962-72.
60. Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011;118:4547-53.
61. Fonseca R, Oken MM. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood. 2001;98:1271-2.
62. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185-91. (Pubitemid 34525505)